Home

Diener Sichern Nickerchen vaccine safety research foundation Adler abfahren Tatsache

South Australian Omicron COVID-19 booster vaccine starting human trials |  Newsroom | University of Adelaide
South Australian Omicron COVID-19 booster vaccine starting human trials | Newsroom | University of Adelaide

10 Reasons to Get Vaccinated - NFID
10 Reasons to Get Vaccinated - NFID

Tuberculosis vaccine candidate VPM1002 safe in HIV- and non-HIV-exposed  newborns as study shows | Max-Planck-Gesellschaft
Tuberculosis vaccine candidate VPM1002 safe in HIV- and non-HIV-exposed newborns as study shows | Max-Planck-Gesellschaft

How have Covid-19 vaccines been made quickly and safely? | News | Wellcome
How have Covid-19 vaccines been made quickly and safely? | News | Wellcome

Vaccine Safety - Vaccinate Your Family
Vaccine Safety - Vaccinate Your Family

Acceptability of Adolescent COVID-19 Vaccination Among Adolescents and  Parents of Adolescents — United States, April 15–23, 2021 | MMWR
Acceptability of Adolescent COVID-19 Vaccination Among Adolescents and Parents of Adolescents — United States, April 15–23, 2021 | MMWR

Houston scientists get Nobel Prize nod for patent-free COVID-19 vaccine |  The Texas Tribune
Houston scientists get Nobel Prize nod for patent-free COVID-19 vaccine | The Texas Tribune

Local Research Study Confirms COVID-19 Vaccine Safety – Med Center Health
Local Research Study Confirms COVID-19 Vaccine Safety – Med Center Health

Vaccine misinformation poised to spike as Covid shots for kids roll out
Vaccine misinformation poised to spike as Covid shots for kids roll out

Anti-vaccine activists are building a legal network : NPR
Anti-vaccine activists are building a legal network : NPR

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against  SARS-CoV-2: an interim analysis of four randomised controlled trials in  Brazil, South Africa, and the UK - The Lancet
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK - The Lancet

Malaria vaccine becomes first to achieve WHO-specified 75% efficacy goal |  University of Oxford
Malaria vaccine becomes first to achieve WHO-specified 75% efficacy goal | University of Oxford

Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine | NEJM
Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine | NEJM

Vaccine Science & Safety - NFID
Vaccine Science & Safety - NFID

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine | NEJM
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine | NEJM

COVID-19 Vaccine Safety | Harvard Medical School
COVID-19 Vaccine Safety | Harvard Medical School

A comprehensive analysis of the efficacy and safety of COVID-19 vaccines:  Molecular Therapy
A comprehensive analysis of the efficacy and safety of COVID-19 vaccines: Molecular Therapy

CIRN Canadian Immunization Research Network
CIRN Canadian Immunization Research Network

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine  BNT162b2 for patients with cancer: interim analysis of a prospective  observational study - The Lancet Oncology
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study - The Lancet Oncology

COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and  safety | Nature Reviews Clinical Oncology
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety | Nature Reviews Clinical Oncology

U.S. Vaccine Safety - Overview, History, and How It Works | CDC
U.S. Vaccine Safety - Overview, History, and How It Works | CDC

Vaccine Safety - Vaccinate Your Family
Vaccine Safety - Vaccinate Your Family

Scientists quit journal board, protesting 'grossly irresponsible' study  claiming COVID-19 vaccines kill | Science | AAAS
Scientists quit journal board, protesting 'grossly irresponsible' study claiming COVID-19 vaccines kill | Science | AAAS

COVID-19 vaccine hesitancy: the five Cs to tackle behavioural and  sociodemographic factors - Mohammad S Razai, Pippa Oakeshott, Aneez Esmail,  Charles Shey Wiysonge, Kasisomayajula Viswanath, Melinda C Mills, 2021
COVID-19 vaccine hesitancy: the five Cs to tackle behavioural and sociodemographic factors - Mohammad S Razai, Pippa Oakeshott, Aneez Esmail, Charles Shey Wiysonge, Kasisomayajula Viswanath, Melinda C Mills, 2021